Erland Construction Completes 28,900sf Fit-out for Affini-T Therapeutics

Watertown, MA – Erland, in collaboration with SmithGroup and RJ Donovan Group, has successfully completed a 28,900sf fit-out of Affini-T Therapeutics’ new headquarters within 100 Forge (Arsenal Yards). The biotechnology company, unlocking the power of T cells against oncogenic driver mutations, occupies the entire top two floors of the 9-story building, encompassing a total of 39,500sf. The new space includes open office areas, conference and huddle rooms, specialty labs, tissue culture and analytical suites, wellness areas, dining areas, and a private wraparound balcony with views of the downtown Boston skyline, Charles River, and Western Hills of Greater Boston.

Erland constructed 100 Forge, the 185,000sf base building that Affini-T has moved into. The cutting-edge lab-ready facility includes 1-level of below-grade parking and a 1-story enclosed mechanical penthouse above the highest occupiable level. The fit-out required an extensive coordination effort to ensure that all the supply, exhaust, and return ductwork, as well as process utilities and electrical needed to support Affini-T’s operations, fit above the ceiling. Material and equipment deliveries were scheduled in advance and performed off hours when needed due to the concurrent construction activities taking place within 100 Forge.

“Erland’s ability to dive right in and get to know us strengthened our communication and improved the project’s overall efficiency,” said Kim Nguyen, Ph.D., Chief Technical Officer, Affini-T Therapeutics. “Their responsiveness and direction not only kept the fit-out on track but also simplified the decision-making process for us.”

Construction was completed in eight months. This was Erland’s first time partnering with Affini-T.

“We’re proud to have partnered with this dynamic group of industry leaders on what we believe to be an extremely successful suburban lab project given the state of the local life sciences market and the associated demand for high-quality working environments with access to luxury amenities,” said Jay Sturdivant, Advanced Technology/Life Sciences Group Manager, Erland. “It’s been a great partnership from the start. The collective efforts of the entire project team immensely contributed to the success of creating an environment that will facilitate groundbreaking research and development.”

About Affini-T Therapeutics
Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.

Affini-T Contacts

Media Contacts
Danielle Cantey
Evoke Canale
Danielle.Cantey@evokegroup.com
619-826-4657

Ian Stone
Evoke Canale
Ian.stone@evokegroup.com 
619-849-5388

Investor Contact
Ailsa Dalgliesh, PhD
ailsa@affinittx.com

About Erland Construction
Over the past 46 years, Erland Construction has successfully grown into the Northeast’s leading open shop construction management firm. The Company is headquartered in Burlington, Massachusetts, and has specialized expertise for new construction and renovations in major market sectors, including advanced technology/life sciences, academic, corporate, commercial, residential, senior living, and hospitality. For more information, visit www.erland.com.